Bio-Pharm Archives - 17 중 15 번째 페이지

Samsung Faces Battery Drain Issue with Galaxy Watch

Samsung, which ambitiously announced its expansion into the healthcare sector, is now facing a significant problem with the rapid battery drain of its smartwatches. This issue follows recent criticism over…

Jang Jawon

2024-07-31

Hanmi Pharmaceutical's Q2 Operating Profit Up 75% To KRW 58.1 Billion

Hanmi Pharmaceutical has achieved robust performance due to strong sales of key products and the growth of its subsidiaries. The company announced on the 30th that it recorded consolidated sales…

Cheon Okhyeon

2024-07-30

Daewoong Pharmaceutical's Bersiporocin Shows Positive Phase 2 Safety Data

Daewoong Pharmaceutical announced on the 29th that its new drug 'Bersiporocin', currently being developed as the world's first treatment for idiopathic pulmonary fibrosis (IPF), has proven its safety in Phase…

Cheon Okhyeon

2024-07-29

ST Pharm's Shift to Deficit in H1: Will H2 Bring a Turnaround?

ST Pharm, which recorded a deficit in the first half of the year, is expected to see a rebound in performance in the second half. On the 26th, the securities…

Cheon Okhyeon

2024-07-26

Why Celltrion’s Retail Investors Oppose the Merger with Celltrion Pharm

“60,000 Celltrion shareholders firmly oppose the merger with Celltrion Pharm, which undermines shareholder value. We strongly urge the company to swiftly announce a clear and detailed stance on the merger…

Cheon Okhyeon

2024-07-26

Will GC Biopharma's Immune Globulin 'Alyglo' Succeed in the U.S. Market?

GC Biopharma Corp's new immune globulin drug 'Alyglo' is set to enter the U.S. market after 8 years of efforts. According to the pharmaceutical industry on the 25th, GC Biopharma…

Cheon Okhyeon

2024-07-25

Daewoong, Unveils 'One Product, One Trillion Won Revenue' Vision

Daewoong Pharmaceutical has unveiled its next growth strategy, the 'One Product, one Trillion Won Plan.' The goal is to achieve sales of over 1 trillion won (approx. $770 million) for…

Jang Jawon

2024-07-24

Samsung Bioepis Secures FDA Approval for High-Cost Rare Disease Drug in the U.S.

Samsung Bioepis announced on the 23rd that it has received approval from the U.S. Food and Drug Administration (FDA) for 'Epysqli' (active ingredient: Eculizumab), a high-cost treatment for rare diseases.…

Cheon Okhyeon

2024-07-23

Celltrion Finalizing Preparations for Third Plant's Commercial Production

Celltrion announced on the 23rd that its third plant, located in Songdo, Incheon, is undergoing final validation before commencing commercial production. Validation is a critical procedure that objectively verifies and…

Cheon Okhyeon

2024-07-23

Following the 'Galaxy Ring' Controversy, Samsung Faces Earphone Troubles

Samsung Electronics has decided to effectively recall its new product, 'Buds 3 Pro', following criticisms of manufacturing and finishing defects. The company recently announced on its website, "We deeply apologize…

Jang Jawon

2024-07-22